Little information is available about the accuracy of different nucleic acid or signal amplification techniques in quantifying human immunodeficiency virus type 1 (HIV-1) RNA in the female genital tract (1, 3, 6, 11) . The ability to assess the viral burden in genital secretions is essential in understanding the pathophysiology of sexual and mother-to-child transmissions of HIV infection (8) and in predicting the effect of antiretroviral therapy at the level of the genital compartment (6, 12) . This will require the availability of standardized assays for the quantification of HIV-1 RNA which should be altogether sensitive, specific, and reproducible. Recently, two commercial hypersensitive assays conceived to detect and quantify low levels of HIV-1 RNA in plasma have become available. These are the AMPLICOR HIV-1 Monitor Test 1.5 (Roche Diagnostics, Branchburg, N.J.), which uses reverse transcription (RT)-PCR and whose threshold of positivity is 50 copies of HIV-1 RNA/ml (13, 14) , and the Quantiplex HIV RNA 3.0 assay (Chiron-Bayer, Emeryville, Calif.), which uses the branched-DNA signal amplification technique and whose lower limit of quantification is 50 copies of HIV-1 RNA/ml (4, 5) . The aim of the present study was to compare the ability of both assays to quantify HIV-1 RNA in normal female genital secretions spiked with HIV-1 RNA standards and in clinical cervicovaginal lavage samples from HIV-infected women.
MATERIALS AND METHODS
Clinical specimens. Cervicovaginal secretions were obtained from 30 HIV-1-seropositive women and from 30 HIV-seronegative healthy women not at risk for HIV. Women with vaginal discharge, genital bleeding, or suffering from a sexually transmitted infection were excluded from the study. Participants were asked to avoid sexual intercourse and intravaginal medications for 3 days before enrollment. Samples were processed within 1 h of collection. Genital secretions were collected outside the menstrual period. Following the introduction of a speculum, a standardized 60-s lavage was performed with 3 ml of 1 M phosphatebuffered saline (pH 7.2) as previously described (2) . This collection procedure introduces a dilution of the genital secretions of about 1:10 (2). After centrifugation of the cervicovaginal lavage at 1,000 ϫ g for 10 min, the cell supernatant was stored at Ϫ80°C. Lavage samples were confirmed to be devoid of a significant amount of contaminating blood by measuring traces of hemoglobin using second derivative spectrophotometry, as described earlier (10, 12) .
HIV-1 RNA panels. Three HIV-1 RNA panels of 1-ml aliquots were prepared with viral stock sources diluted in pooled cell-free cervicovaginal lavages from the HIV-negative control women. Quantitative assays. Evaluation of the HIV-1 RNA load in cervicovaginal lavage samples was assessed by initial concentration of HIV-1 virions, followed by quantitation of HIV-1 RNA in the resulting pellet, using different initial volumes of vaginal lavage sample for each assay. HIV-1 RNA load in cervicovaginal secretions was finally expressed as RNA copies per milliliter of cervicovaginal lavage sample. Quantitative assays for HIV-1 RNA were used according to the manufacturer's recommendations, with slight modifications. For the AM-PLICOR HIV-1 Monitor Test 1.5 assay, the virus concentration was determined by centrifuging 0.5 ml of cervicovaginal lavage samples at 23,600 ϫ g for 60 min at 4°C. The pelleted virus particles were lysed by treatment with 600 l of working HIV-1 MONITOR lysis buffer containing the quantitation standard, and the released RNA was precipitated with 600 l of 100% isopropanol. The precipitated RNA was recovered by centrifugation, washed with 1 ml of 70% ethanol, and resuspended in 100 l of AMPLICOR HIV-1 Monitor specimen diluent. Then, 50 l of the processed specimen was added to 50 l of the working AMPLICOR HIV-1 Monitor master mix for the RT-PCR amplification reactions. Further amplification, hybridization, and detection steps were performed according to the manufacturer's instructions. For the Quantiplex HIV RNA 3.0 assay, the virus was concentrated from 1 ml of cervicovaginal lavage samples by centrifugation at 23,500 ϫ g for 60 min at 4°C, and the supernatant was further discarded without disturbing the virus pellet. Pellets were then frozen at Ϫ80°C for more than 1 day until they could be tested, as recommended. Further hybridization and detection steps were performed according to the manufacturer's instructions.
Statistical analysis. Linear regression analysis on log-transformed values was performed to compare observed to expected values obtained with spiked samples and observed values obtained by both assays in clinical samples, by using the software StatView SE ϩ (Abacus Concepts, Inc., Berkeley, Calif.) and to compare both quantitative assays by using the orthogonal regression Deming method with the EVAL kit software, as described elsewhere (7).
RESULTS
Detection of HIV-1 RNA in spiked samples. Table 1 (Fig. 1) . The mean ⌬log values, as defined by the log of observed RNA level minus the log of the expected RNA level, were Ϫ0.05 for the VQC panel, Ϫ0.08 for the VIH-1/A panel, and Ϫ0.10 for the VIH-1/B panel. All ⌬log values are below the 0.5-log units, which corresponds to the threshold of significant variation for HIV-1 RNA load determination (9) . Of 36 samples, 34 (94%) expected to contain more than 50 HIV-1 RNA copies/ml were detected as positive by the AMPLICOR HIV-1 Monitor Test 1.5, whereas all samples expected to contain fewer than 50 HIV-1 RNA copies/ml were not quantified by this assay. The linear regression analysis of observed versus expected HIV RNA load estimations obtained by the Quantiplex HIV-1 3.0 showed a slope of 1.08 and an r 2 value of 0.92 (P Ͻ 0.001) (Fig. 1 ). Furthermore, 22 tested samples of 58 (39%) showed a significant ⌬log (Ͼ0. The upper values of the dynamic ranges of both assays and the lower value of the dynamic ranges of the AMPLICOR HIV-1 Monitor Test 1.5 assay corresponded to those claimed by the manufacturers, when the assays were used to quantify HIV-1 RNA in cervicovaginal samples, the lower value of the dynamic range of the Quantiplex HIV-1 3.0 assay appeared much lower than 50 copies/ml. Compared to the AMPLICOR HIV-1 Monitor Test 1.5 assay, the Quantiplex HIV-1 3.0 assay yielded higher estimates of HIV-1 RNA concentrations in several tested samples spiked with HIV-1 RNA subtype A as well as subtype B, particularly those containing low amounts of HIV-1 RNA.
Assay reproducibility. To determine intra-assay reproducibility, two pooled cervicovaginal lavages from HIV-seronegative control women spiked with different levels of HIV-1 subtype B RNA representing high and low copy numbers (cervicovaginal secretions samples 1 and 2, respectively) were analyzed simultaneously 10 times by both assays. The results presented in the Table 2 show that the lower-copy-number HIV-1 RNA cervicovaginal secretion sample 2 yielded a slightly larger expected coefficient of variation (CV), compared to the high-copy-number cervicovaginal secretion sample 1 by both assays. However, these values corresponded to a rather narrow within-run standard deviation of Ͻ0.33 log, which is Ͻ0.5 log. The interassay reproducibilities were estimated for the two spiked cervicovaginal secretions samples 1 and 2, by 10 successive determinations of HIV-1 RNA load by both assays. Although the inter-assay reproducibilities of the Quantiplex HIV-1 3.0 assay were slightly higher than those of the AMPLICOR HIV-1 Monitor Test 1.5 assay, the mean CV values for between-run precision showed a rather low variability and were found to be in the range of 0.09 to 0.16%, which still corresponds to a narrow between-run standard deviation (Ͻ0.40 log).
Quantitative analysis of clinical samples. HIV-1 RNA levels were determined in parallel by both ultrasensitive assays in cervicovaginal lavage clinical samples from 30 HIV-1-seropositive women and 30 HIV-seronegative, not-at-risk women (Fig.  2 and Table 3 ).
The AMPLICOR HIV-1 Monitor Test 1.5 and the Quantiplex assays were found positive in 28 (93%) and 29 (97%) of the 30 samples from HIV-infected women, respectively (Fig.  2) . The levels of HIV-1 RNA in cervicovaginal lavages of HIV-positive women ranged from 52 to 750,000 copies/ml (median, 15,300 copies/ml) by the AMPLICOR HIV-1 Monitor Test 1.5 assay and from 75 to 800,000 copies/ml (median, 18,527 copies/ml) by the Quantiplex HIV RNA 3.0 assay. Overall, the differences between the viral load obtained by the AMPLICOR HIV-1 Monitor Test 1.5 and the Quantiplex HIV RNA 3.0 assays varied for 36 samples by no more than 0.5 log. Conversely, 24 (40%) samples showed a significant, i.e., Ͼ0.5-log, discrepancy between the values of HIV-1 RNA level obtained by both assays. The HIV-1 RNA load of these latter samples by the AMPLICOR HIV-1 Monitor Test 1.5 and by the Quantiplex HIV RNA 3.0 assays ranged from Ͻ50 to 12,082 copies/ml (median, 25 copies/ml) and from 100 to 50,572 copies/ml (median, 489 copies/ml), respectively, resulting in a mean difference in the HIV-1 RNA values obtained by both assays of 0.75 Ϯ 0.23 log (mean Ϯ standard error of the mean).
All cervicovaginal lavages samples from HIV-negative women were correctly identified by the AMPLICOR HIV-1 Monitor Test 1.5 assay, whereas 15 (50%) of samples were found positive by the Quantiplex HIV RNA 3.0 assay, i.e., they showed an HIV-1 RNA level above the threshold of positivity of the assay (Fig. 2) . All of these samples were confirmed as negative in a second determination by an in-house RT-nested PCR for the HIV-1 pol gene, as described earlier (15) (data not shown). The levels of HIV-1 RNA in these 15 false-positive samples by the Quantiplex HIV RNA 3.0 assay ranged from 75 to 1,660 copies/ml (median, 232 copies/ml).
Overall, the 60 cervicovaginal samples analyzed showed a positive correlation (r 2 ϭ 0.82) between the values of the HIV-1 RNA loads measured by both assays (P Ͻ 0.0001) (Fig.  2) . If one considers the threshold of positivity defined by the manufacturers, the sensitivity and specificity of the AMPLI-COR HIV-1 Monitor Test 1.5 assay may be estimated to be 93 and 100%, respectively, and the sensitivity and specificity of the Quantiplex HIV RNA 3.0 assay, may be estimated to be 97 and only 50%, respectively.
DISCUSSION
We compared two third-generation hypersensitive assays, the AMPLICOR HIV-1 Monitor Test 1.5 and Quantiplex HIV a The estimated specificity of the assay for cervicovaginal secretion samples corresponding to the ratio of number of true negative samples out of the total number of negative samples, is 30/30 ϭ 100%.
b The estimated specificity of the assay for cervicovaginal secretion samples is 15/30 ϭ 50%.
c A cervicovaginal lavage sample was considered positive if HIV-1 RNA level was above the threshold of positivity, i.e., 50 HIV-1 RNA copies/ml for both assays.
Quantiplex HIV RNA 3.0 assay were 93 and 97%, respectively, indicating that some samples containing a low amount of HIV-1 RNA could not be detected by the AMPLICOR HIV-1 Monitor Test 1.5 assay. The specificity of the AMPLICOR HIV-1 Monitor Test 1.5 assay and that of the Quantiplex HIV RNA 3.0 assay were 100 and 50%, respectively, indicating clearly that the Quantiplex HIV RNA 3.0 assay gives falsepositive results for HIV-negative samples and also overestimates the HIV-1 RNA levels in samples containing copy numbers of HIV-1 RNA under the threshold of detection of the assay. The low specificity of the Quantiplex 3.0 assay used to quantify HIV-1 RNA in cervicovaginal secretions samples suggests that nonspecific hybrization may occur, probably because of the interference with the body fluid matrix. Indeed, we observed that the nonspecific signal was lower when female genital secretions were collected using 10 ml of lavage buffer instead of 3 ml as in the present study (data not shown).
Taken together, our observations demonstrate that the Quantiplex HIV RNA 3.0 assay may lack the specificity to quantify HIV-1 RNA in the acellular fraction of cervicovaginal secretions, the risk of false positivity being particularly marked for the low HIV-1 RNA levels. The AMPLICOR HIV-1 Monitor Test 1.5 assay is highly specific for detecting and quantifying HIV-1 RNA in cervicovaginal secretions, although it may lack sensitivity for some samples with low HIV-1 RNA levels (Յ100 copies/ml).
